Drug Profile
Centatin
Alternative Names: 80-574; 80/574; CDRI 80/574; CDRI 80574Latest Information Update: 25 Aug 2015
Price :
$50
*
At a glance
- Originator Central Drug Research Institute
- Developer Central Drug Research Institute; Zydus Cadila
- Class Antihyperlipidaemics; Pregnadienes
- Mechanism of Action Farnesoid X activated receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hyperlipidaemia
Most Recent Events
- 25 Aug 2015 Phase-III development for Hyperlipidaemia (Combination therapy) is ongoing in India
- 11 Aug 2010 The programme is still in active development
- 29 Oct 2009 This programme is still in active development